Samsung Biologics Co Ltd (207940) - Total Liabilities

Latest as of June 2026: ₩4.29 Trillion KRW ≈ $2.91 Billion USD

Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has total liabilities worth ₩4.29 Trillion KRW (≈ $2.91 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 207940 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Samsung Biologics Co Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Samsung Biologics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Samsung Biologics Co Ltd's balance sheet.

Samsung Biologics Co Ltd Competitors by Total Liabilities

The table below lists competitors of Samsung Biologics Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Banco Santander Brasil SA ADR NYSE:BSBR	USA	$1.17 Trillion
Thomson Reuters Corp TO:TRI	Canada	CA$6.95 Billion
Shanghai Pudong Development Bank Co Ltd SHG:600000	China	CN¥9.46 Trillion
Ferguson Plc NYSE:FERG	USA	$11.91 Billion
BASF SE XETRA:BAS	Germany	€46.47 Billion
Humana Inc NYSE:HUM	USA	$37.92 Billion
AngloGold Ashanti Ltd JSE:ANG	South Africa	ZAC4.81 Billion
CTBC Financial Holding Co Ltd TW:2891	Taiwan	NT$8.78 Trillion

Liability Composition Analysis (2014–2025)

This chart breaks down Samsung Biologics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Samsung Biologics Co Ltd net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.51	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Samsung Biologics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Samsung Biologics Co Ltd (2014–2025)

The table below shows the annual total liabilities of Samsung Biologics Co Ltd from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩3.61 Trillion ≈ $2.45 Billion	-43.88%
2024-12-31	₩6.43 Trillion ≈ $4.36 Billion	+3.47%
2023-12-31	₩6.22 Trillion ≈ $4.21 Billion	-18.19%
2022-12-31	₩7.60 Trillion ≈ $5.15 Billion	+155.05%
2021-12-31	₩2.98 Trillion ≈ $2.02 Billion	+63.19%
2020-12-31	₩1.83 Trillion ≈ $1.24 Billion	+17.23%
2019-12-31	₩1.56 Trillion ≈ $1.06 Billion	-14.67%
2018-12-31	₩1.82 Trillion ≈ $1.24 Billion	-43.09%
2017-12-31	₩3.21 Trillion ≈ $2.17 Billion	-7.07%
2016-12-31	₩3.45 Trillion ≈ $2.34 Billion	+8.32%
2015-12-31	₩3.19 Trillion ≈ $2.16 Billion	+339.42%
2014-12-31	₩724.97 Billion ≈ $491.30 Million	--

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$44.20 Billion

₩65.22 Trillion KRW

Market Cap Rank

#624 Global

#8 in Korea

Share Price

₩1409000.00

Change (1 day)

-0.21%

52-Week Range

₩997000.00 - ₩1609000.00

All Time High

₩1609000.00